FLVCR1 and neoplasm: As demonstrated by encapsulating CAT, NanoICD/CAT-PCA effectively alleviated the immunosuppressive TME and induced robust antitumor immune responses in 4T1 tumor–bearing mice (Fig. 6), significantly suppressing tumor recurrence and lung metastasis, and improving the survival rate of the mice (Fig. 7).